Heart

STRONG

 EDTA CHELATION THERAPY

EDTA CHELATION for HEART DISEASE

EDTA CHELATION THERAPY IN A NUTSHELL:

Who benefits from this therapy?

EDTA Chelation Therapy may be one of the most effective, least expensive, and safest treatments for heart disease ever developed. And, if you have had exposure to lead, mercury, cadmium, and other heavy metals or toxic minerals, this treatment is the gold-standard treatment for the removal of those toxins from your bloodstream.

Image by Aaron Burden

What does this therapy treat?

Because EDTA is so effective at removing unwanted minerals and metals from the blood, it has been the standard FDA-approved treatment for lead, mercury, aluminum and cadmium poisoning for more than 50 years.

  • Heart disease caused by atheroschlerotic plaque

  • Removes unhealthy minerals and metals from the bloodstream such as lead, mercury, aluminum and cadmium

  • Improves calcium and cholesterol metabolism

  • Helps repair cell damage

MORE ABOUT EDTA CHELATION for HEART DISEASE

EDTA Chelation Therapy may be one of the most effective, least expensive, and safest treatments for heart disease ever developed.

With repeated administrations of a weak synthetic amino acid (EDTA, ethylene diamine tetra-acetic acid), atherosclerotic plaque and other mineral deposits are reduced throughout the cardiovascular system by literally dissolving them away.

EDTA exerts its beneficial effects on the body because this molecule is extremely proficient at chemically bonding with mineral and metal ions. Because EDTA is so effective at removing unwanted minerals and metals from the blood, it has been the standard FDA-approved treatment for lead, mercury, aluminum and cadmium poisoning for more than 50 years. EDTA normalizes the distribution of most metallic elements in the body.

It improves calcium and cholesterol metabolism by eliminating metallic catalysts that can damage cell membranes by producing oxygen free radicals and is fast becoming a preferred alternative treatment for heart disease.

The TACT Trial (Trial to Assess Chelation Therapy) was the first large-scale randomized, blinded, placebo-controlled study designed to determine the safety and efficacy of chelation therapy for people who have suffered a heart attack. It was conducted at Mount Sinai Medical Center with 1,708 heart attack survivors. The treatments worked— chelation therapy was found to reduce heart attacks, strokes, deaths, hospitalizations for chest pain, and artery-opening procedures.

Dr. Gervasio Lamas, MD, Chairman of Medicine at Mount Sinai Medical Center and Chief of the Columbia University Division of Cardiology at Mount Sinai Medical Center said, “here is a significant reduction in the primary endpoint of death, myocardial infarction, stroke, coronary revascularization, or hospitalization for angina, with EDTA chelation compared to placebo.

Despite angering some of the anti-alternative medicine crusaders who fought to get the ten-year trial cancelled, the positive results were published in JAMA, the American Heart Journal, and Circulation.[1-3]